Login / Signup

A heart transplant center experience with basiliximab induction strategies: A double edged sword?

Luise HolzhauserMaxwell NorrisMaria MolinaSusan ChambersSwethika SundaravelEman RashedKetan GalaTara FallahTherese BittermannNosheen RezaTeresa S WangPavan AtluriLee R GoldbergRhondalyn McLeanEliot G Peyster
Published in: Clinical transplantation (2024)
Basiliximab reduces the incidence of ACR but increases the risk of AMR, CAV, and may be associated with increased mortality. Mechanistic studies are needed to describe a potential T-cell-escape mechanism with enhanced humoral immunity.
Keyphrases
  • risk factors
  • immune response
  • cardiovascular events
  • heart failure
  • case control
  • atrial fibrillation
  • type diabetes
  • risk assessment
  • climate change
  • antimicrobial resistance